Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,739.60
(
-1.63%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,059.66
(
-3.90%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 80601

Tuesday, 07/07/2009 10:23:27 PM

Tuesday, July 07, 2009 10:23:27 PM

Post# of 257257
ARYX:

tecarfarin…did not achieve the primary endpoint of superiority over warfarin… This was due to the virtually unprecedented performance of warfarin in this trial.

LOL—if I had a dollar for every biotech PR where failure is blamed on an unprecedented performance of the control arm, I’d probably be richer than Buffett.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now